Vantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and care teams with more flexible, collaborative and accessible care options With over 1 million daily interactions with patients across more than 100 countries, Vantive exists to extend lives and expand possibilities for patients everywhere DEERFIELD, Ill., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vantive, formerly the Baxter Kidney Care segment, today launched as a new standalone vital organ ...

In the world of equities, not all stocks shine brightly in the heavens. Some inevitably find themselves in the shadows, struggling against the tides of market sentiment. Such is the case with today’s Bear of the Day, a stock currently enshrouded in bearish clouds, casting doubt on its future trajectory.I’m talking about Zacks Rank #5 (Strong Sell) Baxter ((BAX) ).Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates thro ...

Baxter International (BAX) recently announced the launch of five new injectable pharmaceutical products in the United States, which, when combined with the previous five launches announced in April 2024, marks a total of 10 U.S. injectable product launches in 2024.These new launches reinforce Baxter’s leadership in bringing high-value, specialty injectable products to market to help address critical patient needs. The launches further strengthen Baxter’s Pharamaceutical business segment.Likely Trend of BAX ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________________________ FORM 10-Q _________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C ...

Baxter International Inc. (NYSE:BAX) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Clare Trachtman - Senior Vice President, Chief Investor Relations Officer Joe Almeida - Chairman, President and Chief Executive Officer Joel Grade - Executive Vice President and Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Securities Robert Marcus - JPMorgan Pito Chickering - Deutsche Bank Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Lawrence Biege ...

Baxter International Inc. (BAX) reported third-quarter 2024 adjusted earnings per share (EPS) of 80 cents, which beat the Zacks Consensus Estimate of 78 cents by 2.6%. The bottom line declined 2.4% from the year-ago quarter’s level.On a GAAP basis, the company reported EPS of 27 cents compared with $4.93 in the prior-year quarter.The company reported adjusted EPS from continuing operations, which include Medical Products & Therapies, Healthcare Systems & Technologies and Pharmaceuticals segments, of 49 cent ...

Core Insights - Baxter International reported a revenue of $2.7 billion for the quarter ended September 2024, reflecting a 27.2% decrease year-over-year and a significant miss of 29.72% against the Zacks Consensus Estimate of $3.84 billion [1] - The earnings per share (EPS) for the quarter was $0.80, which is an increase from $0.68 in the same quarter last year, resulting in an EPS surprise of +2.56% compared to the consensus estimate of $0.78 [1] Revenue Performance - Net Sales in Pharmaceuticals (U.S.) were $178 million, below the average estimate of $210.04 million, marking an 8.7% decline year-over-year [3] - International Pharmaceuticals Net Sales reached $410 million, slightly below the average estimate of $417.62 million, with a year-over-year increase of 6.5% [3] - Net Sales in Advanced Surgery were $272 million, exceeding the average estimate of $266.68 million, with a year-over-year growth of 6.7% [3] - Infusion Therapies and Technologies Net Sales were $1.07 billion, slightly above the average estimate of $1.06 billion [3] - Overall, several segments underperformed against analyst estimates, while some showed modest growth year-over-year [3] Stock Performance - Baxter's shares have declined by 2.7% over the past month, contrasting with a 4.9% increase in the Zacks S&P 500 composite [4] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [4]

分组1 - Baxter International reported quarterly earnings of $0.80 per share, exceeding the Zacks Consensus Estimate of $0.78 per share, and up from $0.68 per share a year ago, representing an earnings surprise of 2.56% [1] - The company posted revenues of $2.7 billion for the quarter ended September 2024, which missed the Zacks Consensus Estimate by 29.72%, and compared to year-ago revenues of $3.71 billion [2] - Baxter has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has underperformed the market, losing about 6.8% since the beginning of the year, while the S&P 500 has gained 25.2% [3] - The current consensus EPS estimate for the coming quarter is $0.87 on revenues of $3.98 billion, and for the current fiscal year, it is $2.96 on revenues of $15.22 billion [7] - The Zacks Industry Rank for Medical - Products is currently in the top 32% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

______________________ Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS THIRD-QUARTER 2024 RESULTS • Baxter third-quarter 2024 sales totaled $3.85 billion • Third-quarter total Baxter U.S. GAAP diluted earnings per share (EPS) were $0.27 ; adjusted total Baxter diluted EPS were $0.80 , exceeding the company's previously issued guidance • Third-quarter sales from continuing operations of $2.70 billion increased 4% on both a reported and constant currency basis , reflecting growth across all segments • Third ...

Core Viewpoint - Baxter International Inc. is set to release its third-quarter 2024 results on November 8, with expectations of revenue growth and improved earnings per share compared to the previous year [1][2]. Q3 Estimates - The consensus estimate for revenues is $3.84 billion, reflecting a 3.6% increase from the prior-year quarter [2]. - The consensus estimate for earnings is 78 cents per share, indicating a 14.7% year-over-year improvement [2]. Factors to Note - Baxter anticipates sales growth of 3-4% on a reported basis and 4-5% at constant currency for Q3 [3]. - Adjusted earnings per share are expected to range between 77 cents and 79 cents [3]. Segment Performance - The Medical Products and Therapies segment is likely to benefit from sustained demand and positive pricing, particularly in Infusion Therapies and Technologies, aided by recent FDA approvals [4]. - The Pharmaceutical segment is expected to see growth driven by the U.S. injectables portfolio and new product launches [5]. - The Renal Care segment has shown a recovering trend, with growth in Acute Therapies and Peritoneal Dialysis products, although in-center hemodialysis sales may decline [7]. - The Acute Therapies segment is also expected to benefit from growth in the U.S. and strength in the APAC region [8]. Divestment Plans - The company plans to divest its Renal Care and Acute Therapies segments by late 2024 or early 2025, with discussions ongoing with Carlyle Group for a kidney care spinoff valued at over $4 billion [8]. Operational Efficiency - Ongoing transformation initiatives are likely to enhance operational efficiencies, potentially leading to lower expenses, although inflationary pressures and supply chain constraints may increase costs [9]. Earnings Prediction Model - The current model does not predict an earnings beat for Baxter, as the Earnings ESP is 0.00% and the Zacks Rank is 3 (Hold) [10][11].